|
Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation
|
August 24, 2023
|
PC3I Authors Charu Aggarwal |
International Journal of Radiation Oncology, Biology, Physics
|
|
Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
|
July 27, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Peter Gabriel; Larry Shulman; Justin Bekelman |
JCO Precision Oncology
|
|
Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting
|
July 24, 2023
|
PC3I Authors Charu Aggarwal |
Journal of Clinical Oncology
|
|
Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond
|
July 19, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
MEDI0457 Plus Durvalumab in HPV-associated HNSCC-Response
|
July 14, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens
|
July 14, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Ronac Mamtani; Melina Marmarelis |
Clinical Lung Cancer
|
|
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
|
July 10, 2023
|
PC3I Authors Charu Aggarwal |
Nature Medicine
|
|
Cardiovascular Substructure Dose and Cardiac Events following Proton- and Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer
|
July 6, 2023
|
PC3I Authors Charu Aggarwal |
Advances in Radiation Oncology
|
|
Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
|
June 4, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis; Ronac Mamtani |
JAMA Oncology
|
|
Prospective Feasibility and Phase 1/2 Trial of Preoperative Proton Beam Therapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer
|
May 18, 2023
|
PC3I Authors Charu Aggarwal |
International Journal of Radiation Oncology, Biology, Physics
|
|
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer
|
May 15, 2023
|
PC3I Authors Charu Aggarwal; Christopher A. D’Avella; Melina Marmarelis |
The Oncologist
|
|
Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy
|
May 2, 2023
|
PC3I Authors Charu Aggarwal |
JAMA Network Open
|
|
Re-Evaluating Real-World Evidence in RET Fusion-Positive NSCLC: Are Randomized Clinical Trials Needed?
|
April 22, 2023
|
PC3I Authors Charu Aggarwal; Melina Marmarelis |
Journal of Thoracic Oncology
|
|
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System
|
April 19, 2023
|
PC3I Authors Christopher A. D’Avella; Melina Marmarelis; Charu Aggarwal |
Clinical Lung Cancer
|
|
Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data
|
April 13, 2023
|
PC3I Authors Charu Aggarwal |
JAMA Oncology
|
|
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
|
March 13, 2023
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Adjuvant Atezolizumab Should Be Administered to All Patients With Programmed Death-Ligand 1 Expressing Surgically Resected Stage II to III NSCLC After Chemotherapy: In Favor
|
February 26, 2023
|
PC3I Authors Melina Marmarelis; Charu Aggarwal |
Journal of Thoracic Oncology
|
|
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
|
December 1, 2022
|
PC3I Authors Charu Aggarwal |
Clinical Cancer Research
|
|
Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis
|
December 1, 2022
|
PC3I Authors Charu Aggarwal |
JCO Precision Oncology
|
|
Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?
|
October 3, 2022
|
PC3I Authors Charu Aggarwal |
Journal of Thoracic Oncology
|
